002019 亿帆医药
已收盘 05-29 15:00:00
资讯
新帖
简况
亿帆医药（002019）披露回购股份事项前十名股东持股信息，5月29日股价上涨2.04%
证券之星 · 05-29 22:31
亿帆医药（002019）披露回购股份事项前十名股东持股信息，5月29日股价上涨2.04%
亿帆医药(002019.SZ)拟1亿元至1.2亿元回购公司股份并用于注销
智通财经网 · 05-27 20:08
亿帆医药(002019.SZ)拟1亿元至1.2亿元回购公司股份并用于注销
亿帆医药：截止2026年5月8日公司股东人数为48,084人
证券之星 · 05-27 11:34
亿帆医药：截止2026年5月8日公司股东人数为48,084人
亿帆医药：PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构
证券之星 · 05-27 11:33
亿帆医药：PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构
亿帆医药：公司现金流能满足公司经营需求
证券之星 · 05-27 11:30
亿帆医药：公司现金流能满足公司经营需求
亿帆医药：安徽省中安健康暂无更深度的合作规划
证券之星 · 05-27 11:30
亿帆医药：安徽省中安健康暂无更深度的合作规划
亿帆医药（002019）披露2025年年度分红派息实施公告，5月22日股价下跌0.77%
证券之星 · 05-22
亿帆医药（002019）披露2025年年度分红派息实施公告，5月22日股价下跌0.77%
上海证券：给予亿帆医药买入评级
证券之星 · 05-18
上海证券：给予亿帆医药买入评级
亿帆医药最新公告：全资子公司醋酸地非法林注射液获药品注册受理
证券之星 · 05-15
亿帆医药最新公告：全资子公司醋酸地非法林注射液获药品注册受理
亿帆医药(002019)4月30日股东户数4.84万户，较上期增加0.83%
证券之星 · 05-14
亿帆医药(002019)4月30日股东户数4.84万户，较上期增加0.83%
亿帆医药：截止2026年4月30日公司股东人数为48,393人
证券之星 · 05-14
亿帆医药：截止2026年4月30日公司股东人数为48,393人
亿帆医药：2025年亿立舒美国市场发货累计约4.6万支
证券之星 · 05-14
亿帆医药：2025年亿立舒美国市场发货累计约4.6万支
亿帆医药：若F-652美国AH的IIT研究最终揭盲数据积极，公司将与监管机构沟通后续开发路径
证券之星 · 05-14
亿帆医药：若F-652美国AH的IIT研究最终揭盲数据积极，公司将与监管机构沟通后续开发路径
亿帆医药：主要市场中国和美国均已根据协议约定收到首付款
证券之星 · 05-14
亿帆医药：主要市场中国和美国均已根据协议约定收到首付款
亿帆医药：公司在美国没有新建生产基地的规划
证券之星 · 05-14
亿帆医药：公司在美国没有新建生产基地的规划
亿帆医药：产品价格如上涨将对公司业绩有积极正面的影响
证券之星 · 05-14
亿帆医药：产品价格如上涨将对公司业绩有积极正面的影响
亿帆医药(002019)4月10日股东户数4.74万户，较上期减少1.5%
证券之星 · 05-06
亿帆医药(002019)4月10日股东户数4.74万户，较上期减少1.5%
亿帆医药（002019）2026年一季报简析：净利润同比下降30.25%
证券之星 · 04-25
亿帆医药（002019）2026年一季报简析：净利润同比下降30.25%
亿帆医药(002019.SZ)发布一季度业绩，归母净利润1.07亿元，同比下降30.25%
智通财经 · 04-23
亿帆医药(002019.SZ)发布一季度业绩，归母净利润1.07亿元，同比下降30.25%
亿帆医药：在欧洲已正式上市销售的国家为德国和斯洛文尼亚
证券之星 · 04-20
亿帆医药：在欧洲已正式上市销售的国家为德国和斯洛文尼亚
加载更多
公司概况
公司名称：
亿帆医药股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-13
主营业务：
亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是生物药、化药、中成药、维生素B5、维生素原B5。公司产品曾获得国家科学技术进步奖二等奖，是中国为数不多的在《新英格兰医学》杂志上发表研究成果的中药产品。
发行价格：
12.57
{"stockData":{"symbol":"002019","market":"SZ","secType":"STK","nameCN":"亿帆医药","latestPrice":10.48,"timestamp":1780038237000,"preClose":10.27,"halted":0,"volume":14835637,"delay":0,"changeRate":0.0204,"floatShares":843000000,"shares":1216000000,"eps":0.2925,"marketStatus":"已收盘","change":0.21,"latestTime":"05-29 15:00:00","open":10.25,"high":10.54,"low":10.18,"amount":154000000,"amplitude":0.0351,"askPrice":10.48,"askSize":2,"bidPrice":10.47,"bidSize":77,"shortable":0,"etf":0,"ttmEps":0.2925,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":10.27,"symbolType":"stock","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":11.3,"lowLimit":9.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1216390085,"isCdr":false,"pbRate":1.42,"roa":"--","peRate":35.82906,"roe":"1.21%","epsLYR":0.33,"committee":-0.125828,"marketValue":12748000000,"turnoverRate":0.0176,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-01。","floatMarketCap":8830000000},"requestUrl":"/m/hq/s/002019/","defaultTab":"news","newsList":[{"id":"2639675850","title":"亿帆医药（002019）披露回购股份事项前十名股东持股信息，5月29日股价上涨2.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639675850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639675850?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:31","pubTimestamp":1780065075,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，亿帆医药报收于10.48元，较前一交易日上涨2.04%，最新总市值为127.48亿元。近日，亿帆医药股份有限公司披露《关于回购股份事项前十名股东和前十名无限售条件股东持股信息的公告》。公告显示，公司于2026年5月27日召开董事会，审议通过回购公司股份并用于注销的议案。前十名股东中，程先锋持股496,526,307股，占总股本40.82%；前十名无限售条件股东中，程先锋持股124,131,577股，占无限售条件股份总数14.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0185","BK0239","BK0077","BK0191","BK0070","002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638683283","title":"亿帆医药(002019.SZ)拟1亿元至1.2亿元回购公司股份并用于注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2638683283","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638683283?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:08","pubTimestamp":1779883711,"startTime":"0","endTime":"0","summary":"亿帆医药(002019.SZ)发布公告，公司拟使用自有资金或自筹资金以集中竞价交易的方式回购公司部分股份用于注销并减少注册资本，回购资金总额不低于1亿元(含)，不超过1.2亿元(含)，回购价格不超过17.45元/股(含)。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/14.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/14.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0077","BK0191","BK0197","BK0070","BK0239","002019","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638738578","title":"亿帆医药：截止2026年5月8日公司股东人数为48,084人","url":"https://stock-news.laohu8.com/highlight/detail?id=2638738578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638738578?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:34","pubTimestamp":1779852840,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止5月10日公司最新股东人数？亿帆医药回复：您好，截止2026年5月8日公司股东人数为48,084人。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0191","BK0197","BK0070","BK0239","002019","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638780895","title":"亿帆医药：PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2638780895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638780895?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:33","pubTimestamp":1779852830,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，25年报提到“ 意大利子公司非索医药获得日本 PMDA 认证”，该法规是医疗器械产品的法规，难道非索有生产医疗器械类产品吗？谢谢！亿帆医药回复：感谢您的关注与提问。PMDA（Pharmaceuticals and Medical Devices Agency）全称为“独立行政法人医药品医疗器械综合机构”，是日本负责药品和医疗器械技术审评机构。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0070","BK0185","002019","BK1100","BK1574","159883","BK0239","BK0197","09996","BK1583","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638796578","title":"亿帆医药：公司现金流能满足公司经营需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2638796578","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638796578?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:30","pubTimestamp":1779852633,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董事长，公司股价大幅下跌却不打算回购股票，是否公司资金出现问题了？谢谢亿帆医药回复：感谢您的关注与提问。公司现金流能满足公司经营需求。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002019","BK0070","BK0197","BK0191","159399","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638578795","title":"亿帆医药：安徽省中安健康暂无更深度的合作规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2638578795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638578795?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:30","pubTimestamp":1779852633,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，公司前十大股东中有‘安徽中安健康’的身影，其背后是安徽省投资集团等国资力量。请问公司在安徽肥西等地的研发与生产基地建设，是否与这位国资股东有直接的产业协同？该股东是否会在政策对接、地方产业基金等方面为公司提供实质性支持？期待您的解答。亿帆医药回复：感谢您的关注与提问。安徽省中安健康养老服务产业投资合伙企业（有限合伙）系通过定增方式成为公司股东的，目前暂无更深度的合作规划。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0191","002019","BK0197","BK0070","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637390732","title":"亿帆医药（002019）披露2025年年度分红派息实施公告，5月22日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637390732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637390732?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:36","pubTimestamp":1779442590,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，亿帆医药报收于10.3元，较前一交易日下跌0.77%，最新总市值为125.29亿元。该股当日开盘10.36元，最高10.42元，最低10.26元，成交额达8368.43万元，换手率为0.96%。亿帆医药于2026年5月22日披露《2025年年度分红派息实施公告》。公告显示，公司2025年年度利润分配方案为：以公司总股本1,216,390,085股为基数，向全体股东每10股派1.000000元人民币现金（含税）。本次分红派息股权登记日为2026年5月28日，除权除息日为2026年5月29日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200033011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0197","BK0239","BK0185","BK0191","002019","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636029150","title":"上海证券：给予亿帆医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2636029150","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636029150?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:26","pubTimestamp":1779096415,"startTime":"0","endTime":"0","summary":"上海证券有限责任公司张林晚近期对亿帆医药进行研究并发布了研究报告《亿帆医药2025年年报&2026年一季报点评：自有产品保持增长，研发加速推进》，给予亿帆医药买入评级。2025年公司实现医药营业收入43.58亿元，同比增长2.30%。完成复方银花解毒颗粒治疗儿童流感的Ⅲ期临床试验，并已提交注册申报。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为17.4。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800025537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908397","title":"亿帆医药最新公告：全资子公司醋酸地非法林注射液获药品注册受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635908397?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:19","pubTimestamp":1778840399,"startTime":"0","endTime":"0","summary":"亿帆医药(002019.SZ)公告称，公司全资子公司合肥亿帆生物制药有限公司收到国家药监局签发的醋酸地非法林注射液境内生产药品注册上市许可申请《受理通知书》。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500035414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","BK0077","BK0191","BK0070","BK0239","BK0197","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635790742","title":"亿帆医药(002019)4月30日股东户数4.84万户，较上期增加0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635790742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635790742?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:29","pubTimestamp":1778750981,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亿帆医药披露，截至2026年4月30日公司股东户数为4.84万户，较4月20日增加396.0户，增幅为0.83%。在化学制药行业个股中，亿帆医药股东户数高于行业平均水平，截至4月30日，化学制药行业平均股东户数为3.58万户。从股价来看，2026年4月20日至2026年4月30日，亿帆医药区间跌幅为7.14%，在此期间股东户数增加396.0户，增幅为0.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400030526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0185","BK0077","BK0070","002019","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635768979","title":"亿帆医药：截止2026年4月30日公司股东人数为48,393人","url":"https://stock-news.laohu8.com/highlight/detail?id=2635768979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635768979?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:15","pubTimestamp":1778721321,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年4月 30日公司的股东总数是多少？谢谢亿帆医药回复：您好，截止2026年4月30日公司股东人数为48,393人。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0197","BK0077","BK0239","002019","BK0185","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635686727","title":"亿帆医药：2025年亿立舒美国市场发货累计约4.6万支","url":"https://stock-news.laohu8.com/highlight/detail?id=2635686727","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635686727?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:15","pubTimestamp":1778721321,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药05月13日在投资者关系平台上答复投资者关心的问题。2025年亿立舒美国市场发货累计约4.6万支。美国市场目前存在竞品较多，竞争较为激烈的不利情形，但亿立舒作为新药，较其它长效G-CSF竞品还是有一定的竞争性，目前上市不到一年，公司将与合作伙伴一道努力，尽快实现亿立舒在美国市场的放量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0185","BK0077","BK0070","002019","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635521768","title":"亿帆医药：若F-652美国AH的IIT研究最终揭盲数据积极，公司将与监管机构沟通后续开发路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2635521768","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635521768?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:09","pubTimestamp":1778720952,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司会公布f652在美国二期t临床中期数据吗？若F-652美国AH的IIT研究最终揭盲数据积极，公司将与监管机构沟通后续开发路径；根据公司与合作方的协议约定，ACT001项目上市前的工作主要由合作方负责，公司也将及时获取相关项目进展信息，在合作协议约定可披露的情形下，统一在定期报告中予以披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002019","BK0191","BK0077","BK0239","BK0185","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635768839","title":"亿帆医药：主要市场中国和美国均已根据协议约定收到首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2635768839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635768839?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:06","pubTimestamp":1778720773,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问亿立舒大卖100万，首期里程碑款何时到位，大概金额多少？能否明确一下，年初贵司提及已经达到里程款付款条件了，希望不要回避，给投资者一点信心亿帆医药回复：感谢您的关注与提问。主要市场中国和美国均已根据协议约定收到首付款。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0191","002019","BK0197","BK0070","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635688597","title":"亿帆医药：公司在美国没有新建生产基地的规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2635688597","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635688597?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:06","pubTimestamp":1778720773,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：亿立舒在美国销售已接近一年，4.6万支还没卖完，现在又要在美国新建生产场地，公司这个决策评估过吗？一年卖那么点，有新建场地这个必要吗？亿帆医药回复：感谢您的关注与提问。公司在美国没有新建生产基地的规划。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0077","BK0197","002019","BK0070","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635390768","title":"亿帆医药：产品价格如上涨将对公司业绩有积极正面的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2635390768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635390768?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:06","pubTimestamp":1778720773,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：据了解，近期泛酸钙价格上涨了不少，请问这对公司二季度的营收和利润有正面影响吗？公司近期或下半年会不会调高泛酸钙的出口售价？谢谢！亿帆医药回复：感谢您的关注与提问。（1）产品价格如上涨将对公司业绩有积极正面的影响，具体业绩请您查阅届时公司披露的定期报告；（2）公司B5等维生素产品采取随行就市策略，具体价格可关注博亚和讯网等行业网站。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0197","BK0070","002019","BK0239","BK0185","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633183862","title":"亿帆医药(002019)4月10日股东户数4.74万户，较上期减少1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633183862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633183862?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:23","pubTimestamp":1778059397,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亿帆医药披露，截至2026年4月10日公司股东户数为4.74万户，较3月31日减少721.0户，减幅为1.5%。在化学制药行业个股中，亿帆医药股东户数高于行业平均水平，截至4月10日，化学制药行业平均股东户数为3.61万户。从股价来看，2026年3月31日至2026年4月10日，亿帆医药区间跌幅为0.71%，在此期间股东户数减少721.0户，减幅为1.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600026891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0197","BK0077","BK0185","BK0070","002019","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630873895","title":"亿帆医药（002019）2026年一季报简析：净利润同比下降30.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630873895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630873895?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:21","pubTimestamp":1777069319,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亿帆医药发布2026年一季报。根据财报显示，亿帆医药净利润同比下降30.25%。截至本报告期末，公司营业总收入12.56亿元，同比下降5.36%，归母净利润1.07亿元，同比下降30.25%。去年的净利率为7.28%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500020585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629553978","title":"亿帆医药(002019.SZ)发布一季度业绩，归母净利润1.07亿元，同比下降30.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629553978","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629553978?lang=zh_cn&edition=full","pubTime":"2026-04-23 23:09","pubTimestamp":1776956974,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿帆医药(002019.SZ)发布2026年第一季度报告，第一季度，公司实现营业收入12.56亿元，同比下降5.36%。归属于上市公司股东的净利润1.07亿元，同比下降30.25%。归属于上市公司股东的扣除非经常性损益的净利润1.04亿元，同比增长9.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"亿帆医药(002019.SZ)发布一季度业绩，归母净利润1.07亿元，同比下降30.25%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628429712","title":"亿帆医药：在欧洲已正式上市销售的国家为德国和斯洛文尼亚","url":"https://stock-news.laohu8.com/highlight/detail?id=2628429712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628429712?lang=zh_cn&edition=full","pubTime":"2026-04-20 15:04","pubTimestamp":1776668654,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)04月19日在投资者关系平台上答复投资者关心的问题。投资者提问：除了德国以外，f627目前在欧洲哪些国家已经开始上市销售了？亿帆医药回复：感谢您的关注与提问。在欧洲已正式上市销售的国家为德国和斯洛文尼亚。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000014024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","BK0185","FDXMmain","FDXSmain","FDAXmain","BK0197","BK0070","002019","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780094749191,"stockEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0586},{"period":"3month","weight":-0.2068},{"period":"6month","weight":-0.1276},{"period":"1year","weight":-0.2014},{"period":"ytd","weight":-0.1152}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0227},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"亿帆医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47501人(较上一季度减少1.21%)","perCapita":"17736股","listingDate":"2004-07-13","address":"浙江省杭州市临安区临安经济开发区","registeredCapital":"121639万元","survey":" 亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是生物药、化药、中成药、维生素B5、维生素原B5。公司产品曾获得国家科学技术进步奖二等奖，是中国为数不多的在《新英格兰医学》杂志上发表研究成果的中药产品。","listedPrice":12.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亿帆医药,002019,亿帆医药股票,亿帆医药股票老虎,亿帆医药股票老虎国际,亿帆医药行情,亿帆医药股票行情,亿帆医药股价,亿帆医药股市,亿帆医药股票价格,亿帆医药股票交易,亿帆医药股票购买,亿帆医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}